← boardnext 2027-03next 2028-01-30
MNKD
Mannkind Corporationdistress 0/10 · well-funded / low risk$3.75-2%today-40% from 52w high
Infectious Disease 1Respiratory 1
Lead: Idiopathic Pulmonary Fibrosis (IPF) · est. market ~$5B (approx, global)
Revenue
$90M
Liquidity
$139M
Runway
—
Shares 1y
+1%
Price & events
-36.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.2%
1D
-7.1%
1W
-4.5%
1M
+38.6%
3M
-31.2%
6M
-8.4%
1Y
-36.2%
2Y
-14.1%
5Y
+16.6%
All
Overview
- Market Cap
- $1.16B
- Enterprise Value
- $1.43B
- Volume
- 623.62K
- 52 Week Range
- $2.28 – $6.21
- Total Shares
- 308.95M
- Float Shares
- 302.90M
- Short %
- 8.59%
- % Held by Insiders
- 1.55%
- % Held by Institutions
- 59.23%
- RVOL
- 0.13x
- Beta
- 1.09
Pipeline stages · 3 programs
Technosphere Insulin, Basal insulin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Nintedanib Dry Powder Inhalation
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Clofazimine Inhalation Suspension, Placebo
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-03 Estimated 50% readout ~2027-04-15 | Phase 2 | Technosphere Insulin, Basal insulin | Type 1 Diabetes Mellitus | — | recruiting |
| 2028-01-30 Estimated 50% readout ~2028-03-15 | Phase 2 | Nintedanib Dry Powder Inhalation | Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF) | — | not yet recruiting |
| 2026-06-15 | Phase 1 | MNKD-201(Nintedanib DPI), Placebo | Idiopathic Pulmonary Fibrosis (IPF) | 24 | recruiting |
| 2025-11-10 | Phase 3 | Clofazimine Inhalation Suspension, Placebo | MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous | 132 | terminated |
Catalyst news & presentations · 8
- late 2027Guided 70%readoutAfrezza · Topline data from INHALE-1 studySEC 8-K
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- May 29, 2026PDUFAPDUFAAfrezza · PDUFA target action dateSEC 8-K
- 2026-05-27fda agreementAfrezza · FDA released postmarketing requirement for pulmonary malignancy risk assessmentSEC 8-K
- 2025-11-08trial discontinuedMNKD-101 · Phase 3 trial for refractory NTM lung disease discontinued due to futility; no sputum culture conversion in first 46 participants.SEC 8-K
- October 2025filing acceptanceFiled (NDA/BLA)Afrezza · FDA accepted sBLA for reviewSEC 8-K
- 2025-08-24partnershipDefinitive merger agreement to acquire scPharmaceuticals Inc.SEC 8-K
- 2024-12-17partnershipEntered into exchange agreements with holders of 2.50% Convertible Senior Notes due 2026 to exchange $193.7M principal for 26.7M shares and $89.2M cash.SEC 8-K
Approved drugs (1)
- AFREZZAINSULIN RECOMBINANT HUMAN2014 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $8 (+102% upside) · 8 analysts
- 2026-05-07MizuhoOutperform
- 2026-05-07Wells FargoOverweight
- 2026-05-07RBC CapitalSector Perform
- 2026-05-07HC Wainwright & Co.Buy
- 2026-04-28Wells FargoOverweight
- 2026-04-13MizuhoOutperform
Competitors — Idiopathic Pulmonary Fibrosis (IPF)
- none identified
Recent news
- 2026-07-22Form 4 MannKind Corp For: 21 July By Investing.com - Investing.com South Africa
- 2026-07-22Form 4 MannKind Corp For: 21 July By Investing.com - Investing.com Nigeria
- 2026-07-22MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
- 2026-07-21MannKind EVP David Thomson sells $97,641 in MNKD shares on July 17 By Investing.com - Investing.com South Africa
- 2026-07-21Form 4 MannKind Corp For: 21 July By Investing.com - Investing.com Canada
- 2026-07-21MannKind Executive Sells 123,000 Shares Amid Performance Concerns - Intellectia AI
- 2026-07-20Form 4 MannKind Corp For: 20 July By Investing.com - Investing.com Nigeria
- 2026-07-18MannKind EVP David Thomson sells $97,641 in company stock - Investing.com UK
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.